Literature DB >> 25280997

IL-33/ST2 pathway contributes to metastasis of human colorectal cancer.

Xuejian Liu1, Leilei Zhu2, Xin Lu2, Hairong Bian2, Xia Wu1, Wenchuan Yang1, Qingliang Qin3.   

Abstract

Interleukin-33 (IL-33) was recently implicated in cancer pathogenesis. However, the possible effect of IL-33 on tumor progression of colorectal cancer (CRC), which is one of the most commonly diagnosed and lethal cancers worldwide, was still unclear. Here we evaluated the potential role of IL-33/ST2 pathway in metastasis of human CRC. We found an elevated expression of IL-33 and ST2 in tumor tissues of CRC patients. Higher expressions of IL-33 and ST2 were observed in poor-differentiated human CRC cells. Of note, IL-33 stimulation promoted the invasion of human CRC cells in a dose dependent manner. Enhanced IL-33/ST2 signaling promoted CRC metastasis, while attenuated IL-33/ST2 signaling decreased CRC metastasis. In consistent, enforced IL-33 expression in human CRC cells enhanced their growth, metastasis and reduced the survival time in nude mice, while decreased IL-33 expression in human CRC cells inhibited their growth, metastasis and prolonged the survival time in nude mice. Finally, we observed an increased expression of IL-6, CXCR4, MMP2 and MMP9 in response to IL-33/ST2 signaling in human CRC cells, which were crucial for the enhanced metastasis by IL-33 stimulation. Collectively, our findings demonstrated that IL-33/ST2 pathway could contribute to the metastasis of human CRC, which could enlarge the understanding of CRC pathogenesis and provide clues for developing new CRC therapeutics.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; IL-33; ST2; Tumor metastasis

Mesh:

Substances:

Year:  2014        PMID: 25280997     DOI: 10.1016/j.bbrc.2014.09.106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  53 in total

1.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

2.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

Review 3.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

4.  IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.

Authors:  Min Fang; Yongkui Li; Kai Huang; Shanshan Qi; Jian Zhang; Witold Zgodzinski; Marek Majewski; Grzegorz Wallner; Stanislaw Gozdz; Pawel Macek; Artur Kowalik; Marcin Pasiarski; Ewelina Grywalska; Linda Vatan; Nisha Nagarsheth; Wei Li; Lili Zhao; Ilona Kryczek; Guobin Wang; Zheng Wang; Weiping Zou; Lin Wang
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

5.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.

Authors:  Donye Dominguez; Cong Ye; Zhe Geng; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Long Wang; Zhuoli Zhang; Yi Zhang; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2016-12-23       Impact factor: 5.422

6.  IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer.

Authors:  Yujiang Fang; Lei Zhao; Huaping Xiao; Kathryn M Cook; Qian Bai; Elizabeth J Herrick; Xuhui Chen; Chenglu Qin; Ziwen Zhu; Mark R Wakefield; Michael B Nicholl
Journal:  Med Oncol       Date:  2017-01-05       Impact factor: 3.064

Review 7.  IL-33 in Tumor Immunity: Nothing to Sneeze At.

Authors:  Donye Dominguez; Yi Zhang; Bin Zhang
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

8.  IL-33 activates tumor stroma to promote intestinal polyposis.

Authors:  Rebecca L Maywald; Stephanie K Doerner; Luca Pastorelli; Carlo De Salvo; Susan M Benton; Emily P Dawson; Denise G Lanza; Nathan A Berger; Sanford D Markowitz; Heinz-Josef Lenz; Joseph H Nadeau; Theresa T Pizarro; Jason D Heaney
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

9.  Interleukin-33 and ST2 Signaling in Tumor Microenvironment.

Authors:  Jaewoo Hong; Soohyun Kim; P Charles Lin
Journal:  J Interferon Cytokine Res       Date:  2018-09-25       Impact factor: 2.607

10.  PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.

Authors:  Giuseppe Ercolano; Alejandra Gomez-Cadena; Nina Dumauthioz; Giulia Vanoni; Mario Kreutzfeldt; Tania Wyss; Liliane Michalik; Romain Loyon; Angela Ianaro; Ping-Chih Ho; Christophe Borg; Manfred Kopf; Doron Merkler; Philippe Krebs; Pedro Romero; Sara Trabanelli; Camilla Jandus
Journal:  Nat Commun       Date:  2021-05-05       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.